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AbstrAct
Tumors contain a sub-population of self-renewing and expanding cells known as 
cancer stem cells (CSCs). Putative CSCs were isolated from human melanoma cells of 
a different aggressiveness, Hs294T and A375 cell lines, grown under hypoxia using 
“sphere-forming assay”, CD133 surface expression and migration ability. We found that 
a cell sub-population enriched for P1 sphere-initiating ability and CD133 expression 
also express larger amount of VEGF-R2. Etoposide does not influence phenotype of 
this sub-population of melanoma cells, while a combined treatment with Etoposide and 
Bevacizumab significantly abolished P1 sphere-forming ability, an effect associated 
with apoptosis of this subset of cells. Hypoxic melanoma cells sorted for VEGF-R2/
CD133 positivity also undergo apoptosis when exposed to Etoposide and Bevacizumab. 
When Etoposide and Bevacizumab-treated hypoxic cells were injected intravenously 
into immunodeficient mice revealed a reduced capacity to induce lung colonies, which 
also appear with a longer latency period. Hence, our study indicates that a combined 
exposure to Etoposide and Bevacizumab targets melanoma cells endowed with stem-
like properties and might be considered a novel approach to treat cancer-initiating cells.
IntroductIon
Metastatic melanoma represent one of the most 
aggressive skin cancer, refractory to treatment due to high 
resistance to chemotherapy. Indeed, a 5-year survival rate 
of advanced stage malignant melanoma is less than 10% 
and resistance to chemotherapy, most likely due to the 
presence of cancer stem cells (CSCs), is the major cause of 
treatment failure [1–3]. Several studies have demonstrated 
that tumors contain a small subset of cells that share 
many characteristics with CSCs [4]. They constitute a 
pool of self-renewing cells with the ability of sustaining 
tumor growth and promoting metastatic dissemination. 
The symmetric division of CSCs allows cell population 
expansion while maintaining their distinctive traits [5, 6]. 
Drug resistance is probably the most important clinical 
feature of CSCs, allowing them to play a major role in 
cancer relapse, thereby representing a promising target to 
counteract tumor progression and recurrence [7]. 
Putative CSCs are isolated using methods based 
on several in vitro/in vivo assays, such as expression of 
distinct surface markers or intracellular enzyme activities, 
“sphere-forming” ability in non-adherent culture and/or 
initiation of new tumor growth when xenotransplanted 
into immunodeficient mice [8]. Evidences support the 
presence of CSCs in several malignancies, including 
those of blood, brain, breast and, recently, melanoma 
[9]. Melanoma show phenotypic heterogeneity both 
in vitro and in vivo, suggesting an origin from a cell with 
multi-lineage differentiation ability [10–12]. Moreover, 
Quintana et al. found that transplanting one melanoma 
cell into NOD/SCID Il12rg-/- mice gives rise to a tumor 
in 27% of the cases, indicating that a large population of 
melanoma cells is able of repopulating a new tumor, acting 
as CSC [13]. 
Malignant melanoma is a high vascular tumor 
with constitutive over-expression of vascular endothelial 
growth factor (VEGF) and VEGF receptors (VEGFRs), 
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both associated with poor prognosis [14–16]. Indeed, 
VEGF-R1/VEGF-R2 expression characterizes metastatic 
melanoma cells [17]. Strategies to abrogate angiogenesis 
by inhibiting multiple signaling pathways are attractive 
and Bevacizumab, a humanized monoclonal antibody that 
neutralizes VEGF activity [18–21], and Sorafenib, an oral 
tyrosine kinase inhibitor with multiple targets, including 
VEGFRs [22, 23], are considered very interesting agents. 
However, contrasting results emerge from literature, 
e.g. Adamcic et al. [24] reported a negative effect of 
Bevacizumab on malignant melanoma, whereas Curtarello 
et al. [25] showed a clear effect of Bevacizumab on 
melanoma cells, although on the poorly “aerobic 
glycolytic” subpopulation. 
Recently, we demonstrated that hypoxia induces an 
autocrine aggressive loop in Hs294T metastatic melanoma 
cells involving VEGF and VEGF-R2, and Bevacizumab 
and VEGF-R2 neutralizing antibodies limited the survival 
of hypoxic Etoposide-resistant cells [26]. Etoposide is 
a well-known cytostatic drug acting through apoptotic 
mechanisms. Treatment with Etoposide is more frequent 
in lung cancer, leukemia and testicular tumors, but it 
has been also used in combination with cisplatin for the 
treatment of melanoma brain metastases [27]. However, 
upon Etoposide plus cisplatin exposure, melanoma cells 
switch to a drug-resistance phenotype, associated with an 
apoptotic deficiency [28].
Now, using Hs294T and A375 melanoma cell lines, 
respectively derived from a human metastatic and primitive 
lesion, we demonstrate that a concomitant exposure to 
Etoposide/Bevacizumab eradicates a sub-population 
of melanoma cells endowed with stem-like features. 
Our finding also highlights efficacy of Bevacizumab on 
melanoma cells expressing stem cell markers including a 
functional loop of VEGF/VEGFR2.
results
VeGF-r2 as a target of hypoxic melanoma stem-
like cells
Maintenance of metastatic Hs294T and primary 
A375 human melanoma cells under hypoxic condition 
(1% O2) selected a subpopulation endowed with a stem-
like phenotype, as indicated by their increased ability to 
give rise to melanospheres (primary spheres, P0) in non-
adherent conditions, whereas cells grown in normoxia 
gave spheres in a very small amount. Furthermore, 
melanoma cells from P0 spheres, whether separated into 
single cells, are endowed with higher ability to generate 
secondary spheres (P1) compared to normoxic control in 
both type of melanoma cells (Figure 1A, 1B). Moreover 
data revealed that cells derived from disaggregated 
hypoxic P0 melanospheres were enriched in expression 
of CD133 (Figure 1D, 1E), a well-accepted marker of 
melanoma CSCs [29–34]. However, it is noteworthy to 
consider that hypoxic adherent Hs294T melanoma cells 
express higher level of CD133 compared with that of A375 
cells (Figure 1C). Etoposide (LC50 20 µM) treatment did 
not modify, number of P1 spheres and CD133 expression 
in P0 melanospheres, both in metastatic and primary 
melanoma cells from (Figure 1A, 1B–1D, 1E). The P0 
spheres derived from Hs294T cells showed a bigger 
dimension above those derived from A375 cells, of about 
1.3 fold change. Stem cells like phenotype was confirmed 
by hypoxic increased mRNA expression of NANOG, 
KLF4, OCT4 and SOX2 in both Hs294T and A375 cells 
collected from P0 spheres (Figure 2A, 2B) [32, 33]. 
Further, hypoxic melanoma P0 Hs294T and A375 cells 
show an increased VEGF-R2 expression (Figure 2D, 2E), 
and Etoposide treatment did not modify level of VEGF-R2 
in cells derived from P0 spheres of both cell line analyzed 
(Figure 2D–2E). As reported before for CD133 expression, 
also the expression level of VEGF-R2 in Hs294T is higher 
than that of A375 cells (Figure 2C).
Now, we have analyzed the role of VEGF-R2 and 
potential benefit of Bevacizumab use in reducing cancer 
stem-like cell phenotype in Hs294T cells. Indeed, Hs294T 
cells represent a better model of stemness compared with 
A375 cells. Further, as previously reported impairment of 
VEGF/VEGF-R2 signaling by Bevacizumab increased 
apoptosis rate in Hs294T by reducing reactive oxygen 
species (ROS) derived from NADPH oxidase [26]. 
In Hs294T cells, VEGF-R2-silencing promotes an 
impairment of P1 sphere-forming ability, an effect 
particularly evident when Etoposide treatment was 
associated (Figure 3A). We confirmed the efficacy of 
VEGF-R2 siRNA by Real Time PCR until 72 hours 
(Figure 3B). Hence, we tested whether Bevacizumab may 
cooperate with Etoposide to eliminate the stem-like subset 
population of Hs294T melanoma cells. The concomitant 
treatment with Etoposide and Bevacizumab significantly 
reduced the ability of P0 melanospheres to further 
generate P1 spheres, although Bevacizumab alone was 
found partially active in P1 sphere reduction (Figure 3C). 
Etoposide plus Bevacizumab and also Bevacizumab added 
on silenced VEGF-R2 cells, are effective in inducing 
apoptotic death. Also, Bevacizumab administered as single 
agent increases apoptotic rate of melanoma cells at a level 
very close to that observed using a combined in Figure 3D. 
We also show that Bevacizumab affected VEGF signaling 
by reducing VEGF-R2 phosphorylation. Various studies 
have shown that many anti-cancer drugs kill susceptible 
cells by inducing apoptosis, although is well known that 
melanoma cells are highly resistant to anti-apoptotic drugs 
[35–37]. 
cd133+/VeGF-r2+ Hs294t cell subset 
identified by cytofluorymetric analysis 
We performed a cytofluorymetric analysis which 
allowed us to identify a sub-population of cells positive 
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Figure 1: Hypoxia endows Hs294t and A375 melanoma cells with stem-like traits. (A, b) Starved Hs294T (left) and A375 
(right) cells were cultured under normoxic (21% O2) or hypoxic conditions (1% O2) for 24 h in the presence or absence of Etoposide 
(50 µM). Serum deprived cells in normoxic conditions (21% O2) were used as control. P0 (primary) and P1 (secondary) melanospheres 
were obtained from the above treated cells. Photographs of P0 spheres were taken and shown (above the corresponding treatment), while 
P1 spheres were counted and plotted. (c) Starved Hs294T and A375 cells cultured under normoxic or hypoxic condition for 24 hours and 
treated or not with Etoposide (50 µM). were analyzed for CD133 staining. (d, e) Cells disaggregated from P0 spheres derived from Hs294T 
(left ) and A375 (right) cultured under normoxic or  hypoxic conditions treated or not with Etoposide (50 µM). were analyzed for CD133 
staining. P values of ≤ 0.05 were considered statistically significant *p < 0.05, **p < 0.001, ***p < 0.0001, n = 3.
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for both VEGF-R2 and CD133 (CD133+ /VEGF-R2+ 
cells), and these cells arise with a frequency ranging from 
0.6% in normoxia to 5–7% under hypoxia. As indicated 
by the  plot reported in Figure 4A, the subpopulation 
VEGFR2+ is all included in the CD133+. Data revealed 
that CD133+ subpopulation increases under hypoxia 
and it acquires VEGFR2 expression (Figure 4A, 4B). 
When we analyzed double VEGF-R2+/CD133+ cells 
Figure 2: VeGF-r2 and stem cell like markers are expressed on melanoma cells. (A, b) mRNA evaluation of KLF4, 
NANOG, OCT4, SOX2 was performed in P0 spheres derived from Hs294T (left) and A375 (right). Values are reported as fold change with 
respect to relative normoxic samples. (c) Starved Hs294T and A375 cells were cultured under normoxic or hypoxic condition for 24 hours 
and VEGF-R2 expression was assessed by flow cytometry (d, e) P0 spheres derived from normoxic and hypoxic Hs294T (left) and A375 
(right) cells were disaggregated and VEGF-R2 expression was analyzed by FACS analysis . P values of ≤ 0.05 were considered statistically 
significant *p < 0.05, **p < 0.001, ***p < 0.0001, n = 3.
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for Annexin V expression, we found that Etoposide/
Bevacizumab treatment specifically targets these cells, 
as indicated by the high percentage of AnnexinV+ cells 
of VEGF-R2+/CD133+ subpopulation. On the other 
hand, Etoposide results ineffective on this subpopulation 
of cells (Figure 4C). Data revealed that Etoposide but 
not Bevacizumab is effective in inducing apoptosis of 
VEGF-R2 −/CD133 - subpopulation (Figure 4D). These 
data indicated that VEGF-R2 conferred high intrinsic 
resistance to Etoposide under hypoxic condition and that 
this resistance could be reverted by action of Bevacizumab 
or by neutralization VEGF-R2.
Thereafter, we sorted VEGF-R2+/CD133+ cells 
from hypoxic Etoposide-treated melanoma cells, a 
condition able to reveal higher expression of VEGF-R2 
and CD133 in melanoma cells, and, upon evaluation 
Figure 3: VeGF-r2 targeting abolishes hypoxic stem-like melanoma cells. (A) Hs294T cells were silenced with siRNAs 
against VEGF-R2 or with scramble siRNA as control. 48 hours after transfection, cells were treated with or without Etoposide (50 µM) under 
normoxic or hypoxic conditions for additional 24 hours. Melanosphere formation assay was performed and P1 spheres were quantified. 
(b) VEGF-R2 silencing was confirmed by Real Time PCR under normoxic or hypoxic condition at 24, 48, and 72 hours. Serum deprived 
cells in normoxic conditions were used as control. (c) Hs294T cells were serum starved for 24 hours and then incubated in the presence 
or absence of Etoposide (50 µM) and/or Bevacizumab (250 ng/ml) for 24 h. Melanosphere formation assay was then performed and P1 
spheres were quantified. (d) Apoptotic cell death of Hs294T cells treated or not with Etoposide (50 µM) and/or VEGF-R2 siRNA, and/or 
Bevacizumab for 24 hours, was assessed by Annexin-V/propidium iodide staining. Phosphorylation of VEGF-R2 was analyzed on Hs294T 
cells treated or not with Bevacizumab (250 ng/ml) under normoxic or hypoxic condition. P values of ≤ 0.05 were considered statistically 
significant *p < 0.05, **p < 0.001, ***p < 0.0001, n = 3.
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melanosphere forming ability, we define that these cells 
formed more P1 spheroids (Figure 4E). In CD133+/
VEGF-R2+ cells, sorted by hypoxic-Etoposide cells and 
exposed to Etoposide and/or Bevacizumab, high apoptotic 
rate correlates with Bevacizumab and more importantly 
with the combined treatment (Figure 4E), suggesting 
that Bevacizumab represents a crucial requirement for 
apoptosis of VEGF-R2+/CD133+ cells.
A combined treatment with Etoposide and 
Bevacizumab inhibits invasiveness and lung colonization 
of hypoxic Hs294T stem-like melanoma subset.
To confirm the aggressive behavior of cells derived 
from P0 spheres, we tested Hs294T and A375 cells using 
both two (2D)- and three (3D)-dimensional migration 
assay. Cells derived from disaggregated hypoxic P0 
spheres showed an enhanced migratory ability, and 
Etoposide/Bevacizumab treatment abolishes this capacity 
(Figure 5A–5B). Our data also demonstrated that 
VEGF-R2+/CD133+ subpopulation, sorted from hypoxic 
Etoposide treated cells, expresses a higher migration and 
invasiveness measured in Boyden chambers (Figure 5C). 
Thus, VEGF/VEGF-R2 axis associates with the 
migratory phenotype expressed by melanoma stem-like 
subset. 
Overall, in vitro analyses indicate that Bevacizumab 
cooperates with Etoposide in eradicating VEGF-R2+/
CD133+ cells. Thus, we injected normoxic and hypoxic 
Hs294T melanoma cells treated with Etoposide or 
Etoposide/Bevacizumab into the tail vein of SCID bg/bg 
mice to verify cloning efficiency. Animals were sacrificed 
at different time points and lungs were inspected for 
macro and micro-metastases (see an E&E-stained lung 
section showing a micrometastasis). Mice injected with 
Etoposide-treated hypoxic cells reveal an increased 
number of metastases, starting from day 51, whereas 
addition of Bevacizumab to Etoposide retards appearance 
of lung lesions until day 113, indicating a 2-fold latency 
period for lung colonies development following combined 
treatment, and reduces their number (Figure 5D). A latency 
period of two months in mice corresponds approximately 
to 5.76 years in humans [38]. 
dIscussIon
Melanoma contain a subpopulation with stem 
cell properties defined CSCs and a bulk of more 
differentiated tumor cells. CSC reflect the stage of tumor 
progression and express several abilities, including 
sphere formation. Sphere forming ability was initially 
observed in cultured neural stem cells [39], after that 
was found characterize stem cells of a variety of human 
cancers, suggesting that sphere forming capability 
represents a common growth characteristic of tumor 
stem cells [40]. In 2009, Singh et al. demonstrated 
that neurosphere-derived tumor cells expressing the 
neuronal stem cell surface marker Prominin-1/AC133/
CD133 had an increased capacity for self-renewal and 
proliferation. Only the CD133+ subfraction of brain 
tumor cultures demonstrated the capacity to proliferate 
and generates neurospheres in vitro [41]. Among the 
several microenvironmental aspect of tumors, it is 
recognized that hypoxia drives aggressiveness and 
stemness in tumor cells [42–44]. Indeed, local oxygen 
concentration can directly influence stem cell renewal 
and differentiation. Stem cells might benefit from 
residing in hypoxic niches where oxidative DNA 
damage is reduced. Direct measurement of oxygen 
levels has revealed that bone marrow is in general quite 
hypoxic (1–2% O2) and HIF-1α transcription factor 
plays a major role [45, 46]. Among HIF-1α targets 
there is the ABC glycoprotein transporter MDR1, which 
confers multidrug resistance on a variety of cancer cells 
[46]. Indeed, the ABC transporter, Bcrp/ABCG2, is 
implicated in chemotherapeutic drug resistance in breast 
cancers [47]. 
Our study shows that hypoxic melanoma cells, 
either Hs294T or A375, isolated from P0 spheres express 
an high capacity to induce P1 spheres, level of CD133 
and higher ability of 3D invasiveness and 2D motility 
also in the presence of Etoposide, a pro-apoptotic agent 
active on topoisomerase II [48]. High grade of motility 
was found by Moriyama et al. in CD133+/CXCR4+ 
tumor cells expressing a high metastatic potential [49]. 
We also demonstrated that Etoposide-exposed cells 
isolated from P0 spheres express high level of VEGF-R2 
and treatment with siRNA for VEGF-R2 or Bevacizumab 
abolishes P1 sphere formation. Furthermore, Etoposide 
Bevacizumab cooperation promotes apoptosis in cells 
derived from P0 spheres. It is of importance to note, that 
also Bevacizumab, as a single agent is partially active 
in the reduction of P1 sphere formation and apoptosis 
induction. Hypoxia and VEGF-R2 expression have been 
also correlated with uveal melanoma aggressiveness and 
stem-like behavior [50–51]. 
In addition to melanoma, the VEGF/VEGF-R2 axis is 
involved in tumor progression of acute myeloid leukemia, 
glioma, breast and ovarian cancer [52–54]. Bevacizumab 
has already been approved in combination with 
chemotherapeutic agents for the treatment of metastatic 
colorectal cancers (21, 22). Metronomic chemotherapy with 
daily oral administration of Etoposide plus Bevacizumab 
was used for treatment of malignant glioma [55].
Furthermore, when, by flow cytometry analysis, 
we analyzed VEGF-R2+/CD133+cells for Annexin V 
expression, we found that the combined Etoposide and 
Bevacizumab treatment specifically targets these cells. 
Then, CD133+/VEGF-R2+ cells treated with Etoposide 
and Bevacizumab were sorted and found Annexin V 
positive. Thus, Bevacizumab cooperates with Etoposide 
in eradicating VEGF-R2+/CD133+ cells. Melanoma cells 
with a stem-like phenotype are likely to achieve a drug-
resistant phenotype, including to apoptotic agents, such 
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Figure 4: etoposide and/or bevacizumab treatment eradicated VeGFr-2+/cd133+ subpopulations. (A, b) Cell sub 
populations derived from Hs294T cells cultured under normoxic or hypoxic conditions for 24 hours, were analyzed by FACS for double 
VEGFR-2+ and CD133+ co-expression. (c, d) VEGFR-2+/CD133+(left) and CD133-/VEGF-(right) gated cells were analyzed for 
apoptosis rate evaluated by annexin V /Propidium iodide staining. (e) VEGFR-2+/CD133+ were isolated by cell sorting and used to perform 
a melanosphere (P0 and P1) formation assay. Photographs of P0 spheres were taken and shown (above the corresponding treatment), while 
P1 spheres were counted and plotted. (F) P0 spheres derived from sorted VEGFR-2+/CD133+ and CD133-/VEGF- were treated with 
Etoposide (50 µM) and/or Bevacizumab (250 ng/ml) and apoptosis rate was evaluated by Annexin V/propidium iodide staining.
Oncotarget51145www.impactjournals.com/oncotarget
Figure 5: bevacizumab reduces Hs294t cell motility and in vivo metastases formation. (A, b) P0 spheres from Hs294T, 
treated with or without Etoposide/Bevacizumab (50 µM) and/or Bevacizumab (250 ng/ml), were disaggregated and cells were analyzed 
for migration (left) and invasion (right) assay by Boyden Chamber. (c) CD133+/VEGF-R2+ and CD133−/VEGF-R2- sub population 
were analyzed for cell migration and invasion. (d) Hs294T cells were treated in hypoxic condition with Etoposide (50 µM) alone or with 
Etoposide (50 µM) plus Bevacizumab (250 ng/ml) for 24 h. 1 × 106 melanoma cells treated as above were injected into the lateral tail vein 
of SCID bg/bg mice (n = 5 per group) and number of lung macro and micrometastasis was evaluated at different times from injection (e.g. 
latency). Lungs were inspected for macrometastases using dissecting microscope, and then fixed overnight at 4C in formalin (5% in PBS) 
for histological analyses of micrometastases photo of micrometastasis of mice injected with hypoxic Hs294T cells treated with Etoposide. 
Untreated mice were used as control and they all died at the 51st day of observation **p < 0.001. **p < 0.001, ***p < 0.0001, n = 3.
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Etoposide. However, when the VEGF/VEGFR2 axis will 
be inhibited in these cells, it is possible that cells regain 
apoptotic sensitivity to Etoposide. 
To demonstrate the effectiveness of this 
cooperation, we verified cloning efficiency of hypoxic 
Hs294T melanoma cells treated with Etoposide and/or 
Bevacizumab injected into tail vein of immunodeficient 
mice. We observed an increase latency and a reduced 
lung colonization of Etoposide/Bevacizumab treated sub-
population. The occurrence of lung metastases even after 
a long period in animals injected with melanoma cells 
treated in vitro with Etoposide and Bevacizumab might 
be ascribed to an acquired escaping ability to apoptosis 
of treated CSCs. However, considering that melanoma 
cells were exposed to a single treatment before in vivo 
injection, we may consider the possibility that a multiple 
and adequate schedule of exposure might be instrumental 
in reducing relapse. 
In conclusion, we identified a stem-like cell 
subpopulation from hypoxic Hs294T and A375 human 
melanoma cells, which is specifically targeted in vitro by 
Etoposide and Bevacizumab co-treatment. We therefore 
speculate that Etoposide/Bevacizumab treatment 
could have a role in the control of stem-like subset of 
melanoma.
MAterIAls And MetHods
Unless specified all reagents were obtained from 
Sigma. Hs294T and A375 cells were from ATCC, 
VEGFR2 and pVEGFR2 antibodies for Western Blotting 
were from Santa Cruz Biotechnology. Transwell system 
were from Costar. Low attachment 100 mm plate were 
from Corning.VEGFR-2/KDR-APC (clone:ES8-20E6) 
and CD133/2 (293C3-PE), clone: 293C3 were from 
Miltenyi. PVDF for Western Blot analysis was from 
Millipore. siRNA oligonucleotides targeting VEGF-R2 
protein were obtained from Ambion (ID 221 and ID 222). 
Annexin-V fluorescein isothiocyanate apoptosis kit was 
from Roche Diagnostic. 
cell cultures and transfections 
Hs294T and A375 melanoma cells were cultured 
in Dulbecco Modified Eaglel Medium (DMEM) 
supplemented with 10% fetal bovine calf serum (FCS), 
in 5% CO2 humidified atmosphere. Experiments under 
hypoxic condition (1% O2) were performed in the hypoxic 
incubator. For transient transfections, Hs294T cells were 
plated in six-well plate  cell culture dishes and grown 
to 70% confluence. The siRNA was diluted to a final 
concentration of 20 nM. Transfections were performed 
48 h before the indicated treatment using Lipofectamine 
(Invitrogen), following manufacturer’s recommendations. 
After 48 hours from trasfection cell were treated as 
indicated conditions reported in figure legends.
Flow cytometric analysis and cell sorting
Apoptotic assay
Annexin-V staining was performed using the 
Annexin-V fluorescein isothiocyanate apoptosis kit 
according to the manufacturer’s instructions. Gated cells 
were plotted on a dot-plot showing Annexin-V staining 
and propidium iodide (PI) staining. Index of apoptotic 
cells was determinate adding Annexin V positive 
(early apoptotic) cells to Annexin/PI positive ones (late 
apoptotic). 
Analysis of cd133 and VeGFr2 marker
To analyze the expression of VEGFR2 and CD133 
in A375 and Hs294T cell lines, cells were routinely 
cultured, harvested, trypsin-digested and re-suspended in 
stain buffer (1 × 106 cells in 80 μl). Cells were then treated 
with 20 μl FcR Blocking Reagent for 15 min, and steined 
with antibodies anti-CD133-(PE), and VEGFR2 (APC) 
both diluited (1:11 ) for 30 min. After staining, cells were 
subjected to flow cytometry for analysis using BD FACS 
CANTO II.
cell sorting
To isolate CD133+/VEGFR2+ populations in 
the Hs294T line, cells were digested with Accutase and 
blocked with FcR Blocking Reagent. Propidium iodide 
staining was applied to exclude the dead cells. Live 
cells were incubated with antibodies . Anti-CD133 and 
antiVEGF-R2  were incubated for 30 min and cells were 
sorted by a cell sorter BD FACSARIA III, CA.
Western blot analysis 
1 × 106 Hs294T cells derived from different 
experimental conditions were lysed for 20 min on ice 
in 500 µl of complete RIPA lysis buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 2 mM 
EGTA, 1 mM sodium orthovanadate, 1 mM phenyl-
methanesulphonyl-fluoride, 10 µg/ml aprotinin, 10 µg/ml 
leupeptin). Lysates were separated by SDS/PAGE, and 
transferred into PVDF. Immunoblots were incubated in 
3% BSA, 10 mM Tris/HCl (pH 7.5), 1 mM EDTA, and 
0.1% Tween 20, for 1 h at room temperature, probed 
first with specific antibodies p VEGF-R2 and VEGF-R2 
(1:1000) and then with secondary antibodies (1:500).
rt-Pcr analysis
Total RNA from monolayers or melanospheres 
of A375 and Hs294T melanoma cells was extracted 
using RNeasy (Qiagen) according to the manufacturer 
instructions. Strands of cDNA were synthesized 
using a high capacity cDNA reverse transcription kit 
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(Applied Biosystem) using 1 μg of total RNA. For 
quantification of mRNA expression, Real-Time PCR, 
using Power SYBR green dye (Applied Biosystem) 
was done on a 7500 Fast Real Time PCR system 
(Applied Biosystem). The primers were NANOG: 
5′-ACCTTGGCTGCCGTCTCTGG-3′ (forward), 5′-AGC 
AAAGCCTCCCAATCCCAAACA-3′ (reverse); KLF4: 
5′-GCAGCCACCTGGCGAGTCTG-3′ (forward), 5′-CCG 
CCAGCGGTTATTCGGGG-3′ (reverse); SOX2 5′-GAG 
CTTTGCAGGAAGTTTGC-3′ (forward), 5′-GCAAGAA 
GCCTCTCCTTGAA-3′ (reverse); OCT4: 5′-TTTTGGTA 
CCCCAGGCTATG-3′ (forward), 5′-GCAGGCACCTCAG 
TTTGAAT-3′ (reverse), VEGFR2 GCTTTGGCCCAA 
TAATCAGA (forward), ACACGACTCCATGTTGGTCA 
(reverse). Data were normalized to those obtained with 
Glyceraldehyde-3-phosphate deydrogenase primers. 
Results (mean ± SD) are the mean of three different 
experiments.
Melanospheres formation and treatment
To examine the effects of different agents on 
melanosphere formation, cells were detached using 
Accutase (Sigma) and plated at 1000 cells/cm2 on low 
attachment 100 mm plate in serum-free DMEM/F12  1:1 
(Invitrogen, Carlsbad, CA, USA) supplemented with N2 
(Invitrogen), 0.6% glucose, 20 μg/ml insulin, 10 ng/ml 
b-FGF and 10 ng/ml EGF. Cells were grown under these 
conditions for 15 days to obtain P0 melanospheres. For 
the evaluation of self-renewal, a single melanosphere was 
dissociated in single cells with Accutase, and a diluition 
of 1 cell/well into 96-well low attachment plates was 
performed in order to isolate individual P1 melanospheres. 
After about 10 days single-cell cloning was confirmed by 
microscopic analysis, and single clones were counted. 
P1 spheres were then incubated for 5 days in the absence 
(controls) or presence of testing agent(s). 
Migration and invasiveness assays
Migration and invasiveness of Hs294T and A375 
cell were determined using the Transwell system, equipped 
with polyvinylpyrrolidone-free polycarbonate 8-μm pore-
size filters (diameter, 13 mm). Migration or invasiveness 
assays are distinguished by absence (migration assay) or 
presence (invasiveness assay) of a 3D barrier of Matrigel 
(BD Biosciences). Matrigel was diluted (30 μg in 100 μl 
of H2O), added to top chamber, allowed to solidify for 
1 h at 37°C, and air dried for 16 h. Matrigel barrier was 
reconstituted with 100 μl of Dulbecco’s modified Eagle’s 
medium for 2 h at 37°C before use. Cells were loaded 
into the upper compartment (5 × 104 cells in 200 μl) in 
serum-deprived growth medium. Transwell (coated or not 
with Matrigel) were placed into 24-well culture dishes 
containing 500 μl of Dulbecco’s modified Eagle’s medium 
enriched with 10% serum as a chemoattractant and 
incubated at 37°C for 24 h, under hypoxic or normoxic 
condition. Non-invading cells were mechanically removed 
using cotton swabs, and the microporous membrane 
containing the invading cells was fixed in 96% methanol 
and stained with Diff-Quick staining solution. Invasiveness 
were evaluated counting migrated cells to the lower 
surfaces of polycarbonate filters. Numbers of cells in six 
randomly chosen fields were determined for each filter, and 
means ± SD was plotted.
lung colonization assay
Experiments were conducted in accordance with 
national guidelines and were approved by the ethics 
committee of the Animal Welfare Office of the Italian 
Work Ministry and conformed to the legal mandates 
and Italian guidelines for the care and maintenance of 
laboratory animals. 2 × 106 Hs294T melanoma cells either 
treated with Etoposide or Etoposide plus Bevacizumab 
and suspended in 0.2 ml of PBS were injected into the 
lateral tail vein of six- to eight-week old female SCID-
bg/bg mice (Charles River Laboratories International, 
Wilmington, MA, USA) (five animals per group). Animals 
were monitored every 3 days and sacrificed at different 
time points. Lungs were inspected for metastatic nodules 
with the help of a dissecting microscope, and then fixed 
overnight in 5% formalin in PBS for histological analysis.
statistical analysis
Data are presented as means ± SD from at least three 
independent experiments. Statistical analysis of the data 
was performed using two way Anova Bonferroni Test, and 
p value of ≤ 0.05 is considered statistically significant.
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